{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:24:22Z","timestamp":1778340262352,"version":"3.51.4"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The safety and immunogenicity of M-M-RII (measles, mumps and rubella virus vaccine live, Merck &amp; Co., Inc., West Point, PA)\u2014the only combined measles, mumps and rubella vaccine licensed for use in the United States\u2014were previously reported in pre- and postlicensure clinical trials conducted from 1988 to 2009. M-M-RII continues to be evaluated as a comparator in clinical trials of other vaccines. Here, we review safety and efficacy data from more recent clinical trials of M-M-RII.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a systematic literature review of trials using M-M-RII published from 2010 to 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In the 15 studies that met the inclusion criteria, a total of 12,032 subjects were vaccinated: 7667 persons received a first dose only, 2137 participated in 2-dose studies (128 received 1 dose and 2009 received both) and 2063 received a single dose of M-M-RII as their second dose. Dose number was not specified for 165 participants, \u22656 years old, in 2 studies in which a single dose of M-M-RII was administered. Similar to previous reports, M-M-RII was well tolerated and immunogenic when administered alone or concomitantly with other routinely recommended vaccinations. The most common adverse events included transient injection site pain and fever. Serious adverse events were extremely rare, with only 4 probable or potential vaccine-related events reported among the 12,032 participating subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In trials published from 2010 to 2019, M-M-RII continued to be safe and immunogenic in all age groups studied. These data, along with the results of earlier trials, indicate that the performance of the vaccine has been consistent across more than 30 years of postlicensure studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003273","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T20:01:07Z","timestamp":1627329667000},"page":"1046-1054","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine)"],"prefix":"10.1097","volume":"40","author":[{"given":"Mawuli","family":"Nyaku","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Richardson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Martinon-Torres","sequence":"additional","affiliation":[{"name":"Translational Pediatrics and Infectious Diseases, Hospital Cl\u00ednico Universitario and Universidad de Santiago de Compostela (USC), Galicia, Spain"},{"name":"Genetics, Vaccines, and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigaci\u00f3n Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), Galicia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"R2-20250615","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/INF.0000000000001241","article-title":"Safety and immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in clinical trials of healthy children conducted between 1988 and 2009.","volume":"35","author":"Kuter","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1542\/peds.68.1.18","article-title":"Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27\/3) virus vaccines, singly and in combination.","volume":"68","author":"Lerman","year":"1981","journal-title":"Pediatrics"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus.","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"issue":"suppl 1)","key":"R7-20250615","first-page":"S43","article-title":"Summary and conclusions: measles elimination meeting, 16-17 March 2000.","volume":"189","author":"Katz","year":"2004","journal-title":"J Infect Dis"},{"issue":"suppl 3","key":"R8-20250615","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/505943","article-title":"The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement.","volume":"43","author":"Reef","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamapediatrics.2013.4342","article-title":"Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience.","volume":"168","author":"Papania","year":"2014","journal-title":"JAMA Pediatr"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/bmj.295.6608.1264","article-title":"Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.","volume":"295","author":"B\u00f6ttiger","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199411243312101","article-title":"The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.","volume":"331","author":"Peltola","year":"1994","journal-title":"N Engl J Med"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1473-3099(08)70282-2","article-title":"Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme.","volume":"8","author":"Peltola","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R13-20250615","article-title":"Use of M-M-R II outside of the routinely recommended age range - a systematic literature review [published online ahead of print June 15, 2021].","author":"Pawaskar","journal-title":"Hum Vaccin Immunother"},{"key":"R14-20250615","first-page":"2624","article-title":"Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: a phase III, randomized study.","volume":"14","author":"Abu-Elyazeed","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4161\/hv.20357","article-title":"Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.","volume":"8","author":"Bryant","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/INF.0b013e318279e9a9","article-title":"Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.","volume":"32","author":"Bryant","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.vaccine.2009.10.083","article-title":"Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.","volume":"28","author":"Diaz-Ortega","year":"2010","journal-title":"Vaccine"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.vaccine.2014.04.031","article-title":"Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.","volume":"32","author":"D\u00edaz-Ortega","year":"2014","journal-title":"Vaccine"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1016\/j.vaccine.2018.07.076","article-title":"Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.","volume":"36","year":"2018","journal-title":"Vaccine"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1080\/21645515.2018.1502527","article-title":"Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.","volume":"14","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/21645515.2018.1554971","article-title":"A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.","volume":"15","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.vaccine.2014.02.085","article-title":"Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jpids\/piz010","article-title":"Immunogenicity and safety of a measles-mumps-rubella vaccine administered as a first dose to children aged 12 to 15 months: a phase III, randomized, noninferiority, lot-to-lot consistency study.","volume":"9","author":"Klein","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2011.10.065","article-title":"An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix\u2122) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jpids\/piu081","article-title":"Safety and immunogenicity of human serum albumin-free MMR vaccine in US children aged 12-15 months.","volume":"4","author":"Mufson","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1016\/j.vaccine.2018.01.089","article-title":"A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX\u00ae.","volume":"37","author":"Reisinger","year":"2019","journal-title":"Vaccine"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1097\/INF.0b013e31822256a5","article-title":"Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.","volume":"30","author":"Rinderknecht","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/21645515.2017.1388479","article-title":"Evaluation of immunogenicity and safety of VARIVAX\u2122 New Seed Process (NSP) in children.","volume":"14","author":"Senders","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3181\/00379727-165-40931","article-title":"Clinical and laboratory studies of live attenuated RA 27\/3 and HPV 77-DE rubella virus vaccines.","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1016\/j.vaccine.2012.08.057","article-title":"Measles, mumps, and rubella virus vaccine (M-M-R\u2122II): a review of 32 years of clinical and postmarketing experience.","volume":"30","author":"Lievano","year":"2012","journal-title":"Vaccine"},{"key":"R31-20250615","first-page":"ofaa211","article-title":"MMR vaccine adverse drug reactions reports in the CDC WONDER system, 1989-2019.","volume":"7","author":"Rodriguez-Nava","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R32-20250615","first-page":"1","article-title":"Measles prevention: recommendations of the immunization practices advisory committee (ACIP).","volume":"38","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R36-20250615","doi-asserted-by":"crossref","first-page":"e20162127","DOI":"10.1542\/peds.2016-2127","article-title":"Vaccine delays, refusals, and patient dismissals: a survey of pediatricians.","volume":"138","author":"Hough-Telford","year":"2016","journal-title":"Pediatrics"},{"key":"R37-20250615","first-page":"146","article-title":"Parental hesitancy about routine childhood and influenza vaccinations: a national survey.","author":"Kempe","year":"2020","journal-title":"Pediatrics"},{"key":"R38-20250615","first-page":"104","article-title":"Exploring the reasons behind parental refusal of vaccines.","volume":"21","author":"McKee","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R39-20250615","first-page":"426","article-title":"Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations.","volume":"41","author":"Ventola","year":"2016","journal-title":"P T"},{"key":"R40-20250615","doi-asserted-by":"crossref","first-page":"591","DOI":"10.15585\/mmwr.mm6919e2","article-title":"Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration - United States, 2020.","volume":"69","author":"Santoli","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:04:26Z","timestamp":1750003466000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003273"}},"subtitle":["Clinical Trials of Healthy Children and Adults Published Between 2010 and 2019"],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003273","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}